NCT04103489View on ClinicalTrials.gov

The Use of Eculizumab in HELLP Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 23, 2021

Primary Completion Date

August 31, 2023

Study Completion Date

September 4, 2023

Conditions
HELLP Syndrome (HELLP), Third TrimesterComplement AbnormalityMorbidity;NewbornMaternal InjuryPreeclampsia Severe
Interventions
DRUG

Eculizumab

Participants will receive eculizumab at diagnosis of HELLP syndrome. Participants will receive a maximum of 4 doses.

Trial Locations (1)

21287

The Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Johns Hopkins University

OTHER

NCT04103489 - The Use of Eculizumab in HELLP Syndrome | Biotech Hunter | Biotech Hunter